Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-02-02 00:00:00 ET · period of report 2022-02-01 · accession 0001708138-22-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-02 | 2022-02-01 | REGN | McCourt Marion | EVP Commercial | M - OptEx | $342.93 | +1,000 | 20.6K | +5% | +$342.9K |
| D | 2022-02-02 | 2022-02-01 | REGN | McCourt Marion | EVP Commercial | S - Sale+OE | $607.46 | -1,000 | 19.6K | -5% | -$607.5K |
| D | 2022-02-02 | 2022-02-01 | REGN | McCourt Marion | EVP Commercial | M - OptEx | $0.00 | -1,000 | 8,000 | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-01 | M | A | 1,000 | $342.93 | 20,644 | D | — | — | |
| 2 | Common | Common Stock | 2022-02-01 | S | D | 1,000 | $607.46 | 19,644 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-02-01 | M | D | 1,000 | $0.00 | 8,000 | D | $342.93 · — to 2028-02-12 | 1,000 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |